Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Table 2 Summary of treatment

Treatment strategy	PB-DHL, N (%)
Breast irradiation	31 (64.6)
Sequence of breast irradiation
Breast irradiation with concurrent chemotherapy	11 (22.9)
Breast irradiation following chemotherapy	20 (41.7)
Chemotherapy protocol
R-HyperCVAD	16 (33.3)
DA-EPOCH-R	18 (37.5)
DA-EPOCH-R/MA	14 (29.2)
ASCT	18 (37.5)

PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, ASCT autologous stem cell transplantation

ISSN: 1475-2867